References

1. Alan Guttmecher Institute (AGI). Facts in Brief: Contraceptive Services. Internet: http://www.agi-usa/org/pubs/fb_contr_serv.html.

2. Center for Disease Control and Prevention (CDC). Internet: http:// www.cdc.gov/nchs/release/02news/womenbirths.htm.

3. Bonati, M.; Bortulus, R.; Marchetti, F.; Romero, M.; Tognoni, G. Drug Use in Pregnancy: An Overview of Epidemiological (Drug Utilization) Studies. Eur. J. Clin. Pharmacolo. 1990, 38, 325-328.

4. De Vigan, C; De Walle, H.E.K.; Cordier, S.; Goujard, J.; Knill-Jones, R.; Ayme, S.; Calzolari, E.; Bianchi, F. Therapeutic Drug Use During Pregnancy: A Comparison in Four European Countries. OECM Working Group. Occupational Exposures and Congenital Anomalies J. Clin. Epidemiol. 1999, 52 (10), 977-982.

5. Lacroix, I.; Damase-Michel, C.; Lapeyre-Mestre, M.; Montastruc, J.L. Prescription of Drugs During Pregnancy in France. Lancet 2000, 356, 17351736.

6. Mitchell, A.A.; Hernández-Díaz, S.; Louik, C.; Werler, M.M. Medication Use in Pregnancy, 1976-2000. Pharmacoepidemiology and Drug Safety 2001, 10, S146.

7. Hunt, J.N.; Murray, F.A. Gastric Function in Pregnancy. J. Obstet. Gynaecol. Br. Emp. 1958, 65, 78-83.

8. Parry, B.; Shields, R.; Turnbull, A.C. Transit Time in the Small Intestine in Pregnancy. J. Obstet. Gynaecol. Br. Commonw. 1970, 77, 900-901.

9. Gryboski, W.A.; Spiro, H.M. The Effect of Pregnancy on Gastric Secretion. N. Engl. J. Med. 1976, 155, 1131-1137.

10. Frederiksen, M.C.; Ruo, T.I.; Chow, M.J.; Atkinson, A.J. Theophylline Pharmacokinetics in Pregnancy. Clin. Pharmacol. Ther. 1986, 40, 321-328.

11. Robson, S.C.; Mutch, E.; Boy, R.J.; Woodhouse, K.W. Apparent Liver Blood Flow During Pregnancy: A Serial Study Using Indocyanine Green Clearance. Brit. J. Obstet. Gynaecol. 1990, 97, 720-724.

12. Mendenhall, H.W. Serum Protein Concentrations in Pregnancy: I. Concentrations Inmaternal Serum. Am. J. Obstet. Gynecol. 1970, 106, 388399.

13. Dunlop, W. Serial Changes in Renal Haemodynamics During Normal Human Pregnancy. Br. J. Obstet. Gynaecol. 1981, 88 (1), 1-9.

14. Tsutsumi, K.; Kotegawa, T.; Matsuki, S.; Tanaka, Y.; Ishii, Y.; Kodama, Y.; Kuranari, M.; Miyakawa, L; Nakano, S. The Effect of Pregnancy on Cytochrome P4501A2, Xanthine Oxidase, and N-acetyltransferase Activities in Humans. Clin. Pharmacol. Ther. 2001, 70, 121-125.

15. Wadelius, M.; Darj, E.; Frenne, G.; Rane, A. Induction of CYP2D6 in Pregnancy. Clin. Pharmacol. Ther. 1997, 62, 400-407.

16. Shepard, T.H. Catalog of Teratogenic Agents, 10th Ed.; The Johns Hopkins University Press: Baltimore, 2001.

17. Friedman, J.M.; Polifka, J.E. Teratogenic Effects of Drugs. A Resource for Clinicians (TERIS), 2nd Ed.; The Johns Hopkins University Press: Baltimore, 2000.

18. Schardein, J.L. Chemically Induced Birth Defects, 3rd Ed.; Marcel Dekker, Inc.: New York, 2000; 1-87.

19. Sanz, E.; Gomes-Lopez, T.; Martinez-Quintas, M.J. Perception of Teratogenic Risk of Common Medicines. Eur. J. Obstet. Gynecol. Reprod. Biol. Mar, 2001 95 (1); 127-131.

20. Koren, G.; Bologa, M.; Long, D., et al. Perception of Teratogenic Risk by Pregnant Women Exposed to Drugs and Chemical During the First Trimester. Am. J. Obstet. Gynecol. 1989, Aug, 160 (5 Pt 1), 1190-1204.

21. Reynolds, F. Pharmacokinetics. In Clinical Physiology in Obstetrics; Hytten, F., Chamberlain, G., Eds.; Blackwell Scientific Publications: Boston, 1991.

22. Little, B.B. Pharmacokinetics During Pregnancy: Evidence-based Maternal Dose Formulation. Obstet. Gynecol. 1999, 93, 858-868.

23. Prevost, R.R.; Akl, S.A.; Whybrew, W.D.; Sibai, B. Oral Nifedipine Pharmacokinetics in Pregnancy-induced Hyterternsion. Pharmacother. 1992, 12, 174-177.

24. Guidance for Industry: Population Pharmacokinetics. Internet: http:// www.fda.gov/cder/guidance/1852fnl.pdf, February 1999.

25. Stika, C.E.; Frederiksen, M.C. Drug Therapy in Pregnant and Nursing Women. In Principles of Clinical Pharmacology, Atkinson, A.J. Jr., Daniels, C. E., Dedrick, R.L., Grudzinzkas, C.V., Markey, S.P., Eds.; Academic Press: New York, 2001; 277-291.

26. Office of Human Research Protections, U.S. Department of Health and Human Services. Internet: http://ohrp.osophs.dhhs.gov/humansubjects/guidance/ 45cfr46.htm

27. Guidance for Industry: E6 Good Clinical Practice: Consolidated Guidance. Internet: http://www.fda.gov/cder/guidance/959fnl.pdf, March 1998.

28. Guidance for Industry: E2C Clinical Safety Data Management: Periodic Safety

Update Reports for Marketed Drugs. Internet: http://www.fda.gov/cder/ guidance/1351fnl.pdf, March 1998.

29. Requirements on Content and Format of Labeling for Human Prescription Drugs and Biologies; Requirements for Prescription Drug Product Labels. Federal Register 65 (247), 81082-82231.

30. Reproductive Health Drugs Advisory Committee Meetings. Subcommittee discussion on changes to pregnancy labeling. Internet: http://www.fda.gov/cder/ audiences/acspage/reproductivemeetings1.htm#1999, 6/3/99.

31. Reproductive Health Drugs Advisory Committee Meetings. Presentations and discussion on status of proposed pregnancy labeling changes, status of activities related to preclinical assessment of reproductive toxicity, and FDA draft guidance for industry entitled Establishing Pregnancy Registries. Internet: http:/ /www.fda.gov/cder/audiences/acspage/reproductivemeetings1.htm#1999, 3/28/ 00-3/29/00.

32. Reproductive Health Drugs Advisory Committee Meetings. Identify and discuss those drug and biologic products for which improved pregnancy labeling is critical for: (1) effective prescribing during pregnancy, or (2) proper counseling of pregnant women who have been inadvertently exposed. (Pregnancy Labeling Subcommittee). Internet: http://www.fda.gov/cder/audiences/acspage/ reproductivemeetings1.htm#1999, 9/12/00.

33. Kweder, S.L.; Kennedy, D.L.; Rodriguez, E. Turning the Wheels of Change: FDA and Pregnancy Labeling. The International Society for Pharmacoepidemiology, Scribe Newsletter 2000, 3 (4), 2-4, 10.

34. U.S. Department of Health and Human Services. Healthy People 2010: Understanding and Improving Health, 2nd Ed.; Washington, DC: U.S. Government Printing Office. Internet: http://www.health.gov/healthypeople/ document/, November 2000.

35. Healthy People 2010. Internet: http://www.healthypeople.gov/document/ HTML/Volume2/16MICH.htm#_Toc494699668.

36. American Academy of Pediatrics Work Group on Breastfeeding. Breastfeeding and the Use of Human Milk. Pediatrics 1997, 100 (6), 1035-1039.

37. American Academy of Family Physicians. Breastfeeding (position paper). Internet: http://www.aafp.org/x6633.xml

38. Matheson, I.; Kristensen, K.; Lunde, P.K.M. Drug Utilization in Breastfeeding Women: A Survey in Oslo. Eur. J. Clin. Pharmacol. 1990, 38, 453.

39. Bennett, P.N., Ed. Drugs and Human Lactation, Amsterdam: Elsevier, 1988.

40. Hartmann, P.E.; Changes in the Composition and Yield of the Mammary Secretion of Cows During the Initiation of Lactation. J. Endocrinol. 1973, 59, 231.

41. Larson, G.L.; Smith, V.R., Eds. Lactation. The Mammary Gland/Human Lactation/Milk Synthesis, Academic Press: New York, 1974; Vol. 2.

42. Larson, G.J.; Smith, V.R., Eds. Lactation. The Mammary Gland/Human Lactation/Milk Synthesis, Academic Press: New York, 1978; Vol. 4.

43. Neville, M.C. Anatomy and Physiology of Lactation. Ped. Clin. NA 2001, 48 (1), 13-34.

44. Lawrence, R.A.; Lawrence, R.M. Breastfeeding: A Guide for the Medical Profession, Mosby: St. Louis, 1999.

45. Neville, M.C.; Walsh, C.T. Effects of Drugs on Milk Secretion and Composition. In Drugs and Human Lactation, Bennett, P.N., Ed.; Elsevier: Amsterdam, 1996; 15-45.

46. Lund, I.R.; Romer, J.; Thomasset, N.; Solberg, H.; Pyke, C; Bissell, M.J.; Dano, K.; Werb, Z.; Two Distinct Phases of Apoptosis in Mammary Gland Involution: Proteinase-Independent and -Dependent Pathways. Development 1996, 122, 181.

47. Neville, M.C.; Picciano, M.E. Regulation of Milk Lipid Secretion and Composition. Annu. Rev. Nutr. 1997, 17, 159-184.

48. Committee of Drugs, American Academy of Pedistrics. The Transfer of Drugs and Other Chemicals into Human. Pediatrics 1989, 84, 924.

49. Committee of Drugs, American Academy of Pedistrics. The Transfer of Drugs and Other Chemicals into Human. Pediatrics 1994, 93, 137.

50. American Academy of Pediatrics Committee on Drugs. Transfer of Drugs and Other Chemicals into Human Milk. Pediatrics 2001, 108 (3), 776-789.

51. Briggs, G.G.; Freeman, R.K.; Yaffee, S.J., Eds. Drugs in Pregnancy and Lactation. A Reference Guide to Fetal and Neonatal Risk, 6th Ed.; Williams & Wilkins: Baltimore, 2001.

52. Hale, T. Medication and Mothers' Milk. A Manual of Lactational Pharmacology, 9th Ed.; Pharmasoft Publishing: Amarillo, TX, 2000.

53. Wilson, J.T.; Brons, R.D.; Hinson, J.L.; Dailey, J.W. Pharmacokinetic Pitfalls in the Estimation of the Breast Milk/Plasma Ratio for Drugs. Ann. Rev. Pharmacol. Toxicol. 1985, 25, 667-689.

54. Bennett, P.N., Ed. Drugs and Human Lactation, 2nd Ed.; Elsevier: Amsterdam, 1996.

55. World Health Organization. Levels of PCBs, PCDDs and PCDFs in Breast Milk: Results of WHO-Coordinated Interlaboratory Quality Control Studies and Analytical Field Studies. In Environmental Health Series RPt 34, Yrjanheikki, E.J., Ed.; World Health Organization Regional Office for Europe: Copenhagen, 1989.

56. Berlin, C.M.; LaKind, J.; Sonawane, B.R.; et al. Conclusions, Research Needs, and Recommendations of the Expert Panel: Technical Workshop on Human Milk Surveillance and Research For Environmental Chemicals in the United States. J. Toxicol. Environ. Health A 2002, 65, 1929-1935.

57. Begg, E.J.; Duffull, S.B.; Saunders, D.A.; Buttimore, R.C.; Ilett, K.F.; Hackett, L.P.; Yapp, P.; Wilson, D.A. Paroxetine in Human Milk. Br. J. Clin. Pharmacol. 1999, 48, 142-147.

58. Hagg, S.; Spigset, O. Anticonvulsant Use During Lactation. Drug Saf. 2000, 22, 425-440.

59. Guidance for the Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs. Internet: http://www.fda.gov/cder/guidances, July 1993.

60. Cowett, R.M.; Susa, J.B.; Kahn, C.B.; Gilette, B.; Oh, W.; Schwartz, R. Glucose Kinetics in Nondiabetic and Diabetic Women During the Third Trimester of Pregnancy. Am. J. Obstet. Gynecol. 1983, 146 (7), 773-780.

61. Cowett, R.M. Hepatic and Peripheral Responsiveness to a Glucose Infusion in Pregnancy. Am. J. Obstet. Gynecol. 1985, 155 (3), 272-279.

62. Kalhan, S.C.; D'Angelo, L.J.; Savin, S.M.; Adam, P.A.J. Glucose Production in

Pregnant Women at Term Gestation. Sources of Glucose for Human Fetus. J. Clin. Invest. 1979, 63 (3), 388-394.

63. Kalhan, S.C; Tserng, K.Y.; Gilfillan, C.; Dierker, L.J. Metabolism of Urea and Glucose in Normal and Diabetic Pregnancy. Metabolism 1982, 31 (8), 824-833.

64. Strong, J.M.; Butcher, J.S.; Lee, W.K.; Atkinson, A.J. Absolute Bioavailability in Man of N-acetylprocainamide Determined by a Novel Stable Isotope Method. Clin. Pharmacol. Ther. 1975, 18 (5 Pt 1), 613-622.

65. Abramson, P.P. The Use of Stable Isotopes in Drug Metabolism Studies. Semin. Perinatol. 2001, 25 (3), 133-138.

66. Atkinson, A.J. Drug Absorption and Bioavailability. In Principles of Clinical Pharmacology, Atkinson, A.J., Jr., Daniels, C.E., Dedrick, R.J., Grudzinzkas, C.V., Markey, S.P., Eds.; Academic Press: New York, 2001; 31-41.

67. Byczkowski, J.Z.; Kinkead, E.R.; Leahy, H.F.; Randall, G.M.; Fisher, J.W. Computer Simulation of the Lactational Transfer of Tetrachloroethylene in Rats using a Physiologically based Model. Toxicol. Appl. Pharmacol. 1994, 125 (2), 228-236.

68. Anthony, M.; Berg, M.J. Biologic and Molecular Mechanisms for Sex Differences in Pharmacokinetics, Pharmacodynamics and Pharmacogenetics: Part II. Workshop held at the National Institutes of Health, May 4-6, 1999. Journal of Women's Health & Gender-based Medicine 2002, 11 (7), 617-629.

Was this article helpful?

0 0

Post a comment